SCHEMBL874237

SCHEMBL874237

CCOc1cccc(NC(=O)Nc2ccc(S(=O)(=O)C(CCn3nnc4ccccc4c3=O)C(=O)O)cc2)c1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.53
MAPT P10636 2/20 0.53
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
GPR139 Q6DWJ6 1/20 0.45
MMP1 P03956 1/20 0.42
MMP2 P08253 1/20 0.42
MMP3 P08254 1/20 0.42
MMP9 P14780 1/20 0.42
MMP13 P45452 1/20 0.42
KDM4E B2RXH2 2/20 0.42
HTT P42858 2/20 0.42
HSD17B10 Q99714 1/20 0.42
POLB P06746 1/20 0.42
KMT2A Q03164 3/20 0.42
MEN1 O00255 1/20 0.42
CA2 P00918 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL874274 0.85 MMP2 (0.48) SMN1; SMN2MAPTGPR139MMP1MMP2
SCHEMBL875118 0.82 TSHR (0.52) SMN1; SMN2MAPTNPC1RAB9AGPR139
SCHEMBL874772 0.81 KMT2A (0.47) GPR139KDM4EHTTHSD17B10KMT2A
SCHEMBL877315 0.81 LMNA (0.47) MAPTGPR139KDM4EHTTPOLB
SCHEMBL874492 0.80 KMT2A (0.49) MMP1MMP2MMP3MMP9MMP13
SCHEMBL878059 0.80 GPR139 (0.46) SMN1; SMN2MAPTGPR139HTTHSD17B10
SCHEMBL877579 0.80 KMT2A (0.50) MAPTGPR139MMP1MMP2MMP3
SCHEMBL875017 0.80 HTT (0.47) SMN1; SMN2MAPTGPR139KDM4EHTT
SCHEMBL877932 0.80 KMT2A (0.47) NPC1KDM4EHTTHSD17B10POLB
SCHEMBL875478 0.79 MMP2 (0.52) GPR139MMP1MMP2MMP3MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140148459-A1 MATRIX METALLOPROTEINASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2014-05-29 US claimed
US-20140148459-A1 MATRIX METALLOPROTEINASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2014-05-29 US disclosed
EP-2619185-A1 MATRIX METALLOPROTEINASE INHIBITORS Ranbaxy Laboratories Limited (IN) 2013-07-31 EP disclosed
WO-2012038942-A1 MATRIX METALLOPROTEINASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2012-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140148459-A1 MATRIX METALLOPROTEINASE INHIBITORS MMP9, MMP12, MMP10 SMN1; SMN2 3367/4885MAPT 2663/4885NPC1 1027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.